BioSpace News Archive

Leading NMR diagnostics company numares recently published data showing that its novel, multi-marker approach to assess kidney function allowed for a more precise estimation of glomerular filtration rate by a simple serum test.

Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, announced that it has closed a $50 million Series B financing.

Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the “Company”), a developer of Veto Cell-based innovative immunotherapy technologies that facilitate mismatched donor stem cell (e.g. bone marrow) and organ transplants and other cell therapy treatments with an improved safety profile achieved through the active management of immune response,

Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland

Hydrocephalus is a neurological condition, wherein cerebrospinal fluid builds in the ventricles and choroid plexus.

Radiotherapy or radiation therapy has been a key pillar of the palliative and curative care for cancer patients.

Monoclonal antibodies assume a significant job in indicative prescription during tests to decide the centralization of explicit proteins in blood or pee.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing n

Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune disease.